While setmelanotide is currently approved only for rare genetic types of obesity, its ability to reduce leptin resistance suggests potential for use in non-genetic forms of obesity and in combination therapy with leptin, both of which warrant further investigation in future studies. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.